Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remune + Amplivax in HIV/AIDS
NCT02366026Phase 3Unknown
- Sponsor
- Immune Response BioPharma, Inc.
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Remune + Amplivax with Amplivax Placebo (2 arms). Primary endpoint: HIV Viral Load at 52 weeks. Status: unknown.
02
Drugs
Remune
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02366026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366026.